A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries

NCT04399551 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

437

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: CAB OLI
DRUG: CAB LA
DRUG: RPV OLI
DRUG: RPV LA
OTHER: Continuous Quality Improvement (CQI) calls

Sponsor

ViiV Healthcare

Collaborators

[object Object]